Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00026832 · ClinicalTrials.gov registry record
Examination of Brain Serotonin Receptors in Patients With Mood Disorders
A clinical trial, sponsored by National Institute of Mental Health (NIMH).
- Completed
- Registry status
- 214
- Enrollment target
NCT00026832: Completed study, sponsored by National Institute of Mental Health (NIMH).
NCT00026832 is a clinical trial that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 214 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00026832 has completed, sponsored by National Institute of Mental Health (NIMH).
- COMPLETED
- Registry status
- 214 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the function of certain brain chemicals and receptors in patients with mood disorders. This study will also examine how the stress hormone cortisol affects brain function. Data suggest that serotonin 1A (5-HT1A) receptor function is abnormal in patients with mood disorders, such as major depressive disorder (MDD) and bipolar disorder (BP). However, these data are limited because they are based on small sample sizes. In this study, PET scans will be used to compare 5-HT1A receptor binding potential between mood disorder patients and healthy volunteers. All participants will have an initial medical and psychiatric evaluation. Depression severity, anxiety, negative thinking, level of functioning, intelligence, and cognitive functions will be measured. Urine, saliva, and blood will be collected. Women will have a pregnancy test and tests to determine menstrual phase and time of ovulation. Participants will undergo magnetic resonance imaging (MRI) and PET scans of the brain. Some participants will have other procedures such as a lumbar puncture. Participants with Cushing's disease will undergo imaging as a comparison group.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 214 participants |
| Start Date | 2001-10-04 |
| Est. Completion | 2012-11-27 |
What the finished NCT00026832 record still lists
NCT00026832 is an observational study that tracks outcomes without assigning an intervention. The registered 214 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00026832 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00026832 about?
NCT00026832 is a clinical study titled "Examination of Brain Serotonin Receptors in Patients With Mood Disorders". The purpose of this study is to evaluate the function of certain brain chemicals and receptors in patients with mood disorders. This study will also examine how the stress hormone cortisol affects brain function. Data suggest that serotonin 1A (5-HT1A) receptor function is abnormal in patients with...
What is the current status of trial NCT00026832?
This trial is currently completed. The enrollment target is 214 participants. The study started on 2001-10-04. Estimated completion is 2012-11-27.
Who is sponsoring clinical trial NCT00026832?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04030507 · 214 participants · NA
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
- NCT04421248 · 214 participants · Phase 4
Biomarker Validation in Motor System Physiology in Attention Deficit Hyperactivity Disorder
- NCT04667520 · 214 participants · NA
Testing a Lifestyle Physical Activity Intervention for Women With Depression in Alcohol Treatment
- NCT05418868 · 214 participants · Phase 1
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI